2022 ACC Expert Consensus Decision Pathway on Nonstatin Therapies for LDL-C Lowering

Statins are the foundation, but for a large group of high-risk patients they are not enough. This ACC decision pathway is the practical answer to the question that follows: when a maximally tolerated statin leaves LDL cholesterol still too high, what comes next, and in what order?

Its value is sequence, not novelty. The document lays out stepwise algorithms organized by patient population — established disease, very high risk, familial hypercholesterolemia — and walks the clinician through escalation: confirm adherence and intensity, add ezetimibe, then add a PCSK9 inhibitor, with the newer agents bempedoic acid and inclisiran folded into the 2022 update. Each step is tied to an LDL threshold that triggers the next. It turns a confusing menu of drugs into a checklist.

The honest framing is that this is a decision pathway, not a guideline — expert consensus filling the space between the evidence and the bedside. It does not generate new trial data; it organizes existing recommendations into something a busy clinician can actually follow.

We rate the evidence strong. The underlying agents rest on solid outcomes trials, and the document’s contribution — a clear, ordered route to getting LDL low when one drug won’t do it — is exactly the kind of operational clarity that separates a good treatment plan from a stalled one.